Office-based cardiovascular risk prediction continues to challenge practitioners in primary and secondary risk stratification settings. In patients with established peripheral arterial disease (PAD), the risk of cardiovascular events (i.e. death or morbidity due to coronary heart disease and/or cerebrovascular disease) is high, yet traditional risk factors and the ankle-brachial index (ABI) do not provide a complete secondary risk prediction. In this population, office-based cardiovascular risk stratification may be improved by surrogate markers of the systemic atherosclerotic burden, as well as markers of systemic inflammation. This review will evaluate the utility of the ABI, clinical stage of disease, and the emerging role of C-reactive protein (CRP) and other inflammatory markers in secondary risk prediction in PAD. Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation.
Introduction
Office-based identification of patients at high risk for cardiovascular events is becoming more important in primary and specialty care due to the escalating prevalence of cardiovascular disease in the United States, and poor outcomes in patients with underlying cardiovascular disease. Risk management in the setting of existing atherosclerotic vascular disease therefore remains a major health challenge. 1 Recent research has focused on secondary risk prediction in the peripheral arterial disease (PAD) population.
Patients with established PAD have a cardiovascular event rate similar to patients with established coronary heart disease (CHD). For example, studies have demonstrated that the rate of myocardial infarction (MI), ischemic stroke and vascular death in persons with PAD ranges from 4 to 7 per 100 patient years, which is similar to the risk in patients with established coronary or cerebral vascular disease. 2, 3 In one population study, an abnormal resting ankle-brachial index (ABI) was associated with a sixfold increased risk of cardiovascular death, independent of other traditional risk factors for CHD. 4 However, no risk prediction tools have been established among patients with PAD to identify who is likely destined for an acute event. A secondary risk stratification tool for PAD patients would not only provide more accurate cardiovascular prognostic information, it would also provide objective, individualized data that may assist providers in stressing the importance of lifestyle modification, and adherence to medical therapies.
Current primary cardiovascular risk assessment involves the application of traditional cardiac risk factor analysis often using equations derived from large observational studies such as the Atherosclerosis Risk in Communities (ARIC), Framingham, Honolulu, and Strong Heart studies. 5, 6 Further risk stratification in the PAD population may be informed by several factors, including underlying comorbid diseases, clinical stage of PAD (claudication versus critical leg ischemia) and hemodynamic severity of disease (ABI).
Clinical staging may ignore the importance of other factors which may also be key independent contributors to long-term survival, including markers of systemic inflammation and abnormalities of endothelial function. Thus, improving cardiovascular risk assessment may require another approach, such as looking for biologic markers that reflect components of the pathophysiology of acute cardiovascular events. 7 Advances in vascular biology and understanding of the pathophysiologic processes that lead to plaque rupture have led to an expanding literature linking cardiovascular disease to maladaptive changes in the systemic inflammatory milieu and endothelial dysfunction. Elevated markers of inflammation, particularly C-reactive protein (CRP), are associated with poor outcomes in patients with coronary artery disease, and there is an increasing body of evidence in PAD patients linking this marker to adverse cardiovascular events.
This review will therefore assess the role of the ABI, clinical stage of disease, and polyvascular disease (clinical evidence of atherosclerotic disease in more than one circulation) in the prediction of risk of future cardiovascular events in PAD patients, and will explore whether selected markers of inflammation can enhance risk prediction.
The ABI for secondary risk assessment in PAD
Among otherwise healthy patients, an abnormal ABI is a powerful marker of cardiovascular risk, particularly for those in the medium Framingham risk category. [8] [9] [10] [11] [12] [13] [14] In patients with established PAD, there may be additional value in assessing the abnormal ABI spectrum as it decreases below 1.00. Analyses of many population cohorts with lower extremity PAD show a strong inverse relationship between decreased ABI and higher non-fatal cardiovascular events, as well as higher cardiovascular and total mortality. 3, 4, 8, [15] [16] [17] [18] [19] However, several studies have had conflicting results. [20] [21] [22] McDermott and colleagues studied over 400 patients with ABIs less than 0.92 seeking to further risk stratify survival according to the degree of lower extremity ischemia based on ABI findings. 21 Although patients with an ABI less than or equal to 0.30 had lower cumulative survival over 4.3 years, no significant difference was found between patients with ABIs between 0.31 and 0.49 versus those with ABIs between 0.50 and 0.92 after multivariate adjustment for cardiovascular risk factors and comorbidity, including the presence of critical limb ischemia (CLI).
Several studies have also shown that non-fatal cardiovascular events have not correlated with the degree of lower extremity ischemia based on ABI severity among PAD patients. 4, 10, 23, 24 O'Hare and colleagues recently assessed cardiovascular risk across the ABI spectrum in 5748 patients in the Cardiovascular Health Study. 24 Over 11 years of follow-up, adjusted hazard ratios for cardiovascular events were not higher in patients with an ABI of less than 0.61 (HR 1.60, CI 1.09-2.34) or those with an ABI of 0.61-0.70 (HR 1.57, CI 1.07-2.2) compared with those with an ABI of 0.71-0.80 (HR 1.63, CI 1. 16-2.28) . In that study, the clinical stage of disease was not included in the adjustment.
Thus, as illustrated in Table 1 , while an abnormal ABI clearly identifies a high-risk population, the ABI value in patients with established PAD may not provide complete information on the future risk of cardiovascular events.
Clinical staging for secondary risk assessment in lower extremity PAD
Assessing the clinical stage of lower extremity PAD may provide information regarding future cardiovascular risk separate from ABI per se. There are several clinical definitions of the stage of PAD including criteria developed by Rutherford and also by Fontaine that grade the continuum of ischemic signs and symptoms from asymptomatic disease to intermittent claudication to major tissue loss. 25 Based on these clinical classifications, the clinical spectrum of symptomatic PAD can usually be assessed with a thorough history.
The annual overall major cardiovascular event rate (non-fatal MI, stroke and vascular death) in PAD patients is 4-7% as stated above. 8 Among these patients, those with intermittent claudication or atypical leg symptoms on exercise have an approximately twofold higher risk of total, coronary, and cardiovascular mortality versus asymptomatic PAD patients, but the data are not conclusive. 26, 27 In a study of 1592 patients, Leng and colleagues found that symptomatic PAD patients had a lower relative risk of all-cause mortality and no difference in cardiovascular events compared with asymptomatic patients. 28 Also, in the Limburg Study of PAD patients with an ABI Ͻ 0.95, a history of claudication did not independently predict worse cardiovascular morbidity or mortality. 29 CLI denotes the presence of rest pain or tissue loss due to severe ischemia. Approximately 5% of the patients with intermittent claudication will develop CLI in 5 years. 30 In contrast to the event rates in asymptomatic PAD and claudication, virtually all (95%) patients who present with ischemic gangrene, and 80% of those presenting with rest pain, are dead within 10 years. 31 The fatal and non-fatal cardiovascular event rate in CLI patients approaches 20% at 1 year and 40-70% at 5 years. Those who survive are at high risk for infection and amputation. 32 In one study comparing prognosis in symptomatic PAD patients, the presence of CLI was associated with a greater than threefold risk of all-cause and cardiovascular mortality compared with patients with intermittent claudication. 33 However, more recent studies of drug therapy in patients with CLI has shown improved event rates which suggest a better natural history than older studies. 34 Nonetheless, it is evident that patients progressing to CLI carry the worst cardiovascular and overall prognosis.
Although it is accepted that symptomatic PAD increases risk of future events, there are limitations to using the clinical stage of disease to stratify patients by risk of cardiovascular events. Classic claudication is present in only one of five PAD patients and some studies have demonstrated lower rates of claudication as shown in the Rotterdam study, where only 1.9% of PAD patients older than 55 had symptoms. 35 The presence of symptomatic PAD is further obscured by the fact that 40-50% of the reported leg symptoms in PAD patients are atypical. 36 In summary, the clinical severity of PAD is a strong predictor of outcomes, particularly in patients who have CLI. What is not known is whether ABI and clinical stage are highly correlated or provide independent prediction of systemic outcomes in PAD. For example, does a patient with an ABI of 0.60 who has no ischemic leg symptoms at rest have the same natural history as a patient with the same ABI but who presents with an ischemic ulcer?
Impact of polyvascular disease
Patients with chronic, stable atherosclerosis in any arterial bed are at higher risk of cardiovascular events than patients without atherosclerosis. In turn, patients with clinical disease in two or more circulations are at much higher risk. In PAD patients, a survey of atherosclerotic burden in other tissue beds has prognostic implications as polyvascular disease involving two or more of the coronary, peripheral, or cerebral arterial beds is a powerful predictor of increased future cardiovascular risk. 26, [37] [38] [39] Polyvascular disease is very common in the PAD population. For example, in the PARTNERS program of almost 7000 US primary care Table 1 Selected studies of total mortality, cardiovascular mortality, and cardiovascular morbidity across the ABI spectrum.
patients, over 50% of outpatients with PAD had a history of coronary artery disease. 40 Polyvascular disease was recently evaluated in over 67,000 international patients enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 41 In that registry, concomitant involvement of symptomatic atherothrombosis in the lower extremities, cerebral, and/or coronary circulation was prevalent in almost 16% of the international population evaluated. The registry confirmed in a fully adjusted model that while patients with isolated PAD had a 1-year cardiovascular event (cardiovascular death, MI, stroke, or cardiovascular-related hospitalization) rate of 17.4%, those with both CHD and PAD had a rate of 23.1%, and those with CHD, PAD, and cerebrovascular disease had a rate of 26.3%, as illustrated in Figure 1 . 42 Thus, another means to risk stratify patients with established PAD is to determine the number of other regional manifestations of atherosclerosis.
Novel markers of cardiovascular risk
An assessment of secondary risk markers in the PAD patient should expand beyond traditional risk factors to include a survey of hemodynamic and clinical disease markers as reviewed above. Nonetheless, each of these variables has limitations and further appraisal of these high-risk patients may require evaluation of novel markers of risk.
Markers of systemic inflammation and hemostasis have an established evidence base in secondary risk assessment in patients with CHD, and new data are emerging in PAD. Multiple biomarkers including C-reactive protein (CRP), serum amyloid A (SAA), interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor alpha (TNF␣), D-dimer, fibrinogen, and cellular adhesion molecules have been evaluated. [43] [44] [45] [46] [47] From this list, CRP has demonstrated the most potential in risk assessment to date. CRP, a primarily liver-derived acute phase protein, has been demonstrated in atherosclerotic plaque and may promote atherosclerosis itself by depositing into the intima and attracting monocytes which express a CRP receptor. 48, 49 There is still some debate as to whether CRP is causative or a response to the atherosclerotic process. 44 Elevated CRP is independently associated with coronary, cerebral, and peripheral arterial events in both healthy individuals and those with established CHD. [49] [50] [51] The added value of CRP and other inflammatory markers in primary risk prediction has been questioned, but CRP has been shown to be useful for predicting the risk of recurrent cardiovascular events in patients with established CHD. [52] [53] [54] [55] [56] [57] The Centers for Disease Control and the American Heart Association have endorsed the use of CRP as an independent marker of increased risk for recurrent cardiovascular events, including death and MI in patients with established CHD. 58
CRP and secondary risk prediction in PAD patients
The role of CRP for prediction of future cardiovascular events in patients with PAD has been evaluated on a limited basis. A recent analysis of patients with severe PAD (mean ABI of 0.51 and scheduled to undergo lower extremity bypass) revealed that postoperative cardiovascular and graft-related adverse outcomes were associated with CRP after multivariate adjustment, while fibrinogen and SAA were not associated. 59 Figure 1 One-year outcomes in PAD patients in the REACH registry. 42 Vainas and colleagues evaluated CRP levels in 387 lower extremity PAD patients with a mean ABI of 0.64 at inclusion. Baseline CRP levels were elevated in all patients and 2-year outcomes were stratified to tertiles of CRP. 49 The combined endpoint of all-cause mortality and/or any cardiovascular complication was significantly higher from the low-CRP group to the high-CRP group during follow-up, even after correction of classic cardiovascular risk factors and clinical severity of PAD. Rossi and colleagues performed a similar study of 51 PAD patients who were undergoing lower limb revascularization. 50 After baseline CRP levels were drawn, patients were followed for 2 years after their surgeries and outcomes were expressed by tertiles of CRP. After multivariate analysis, including adjustments for Eagle score index and previous CAD, only CRP was associated with the risk of fatal and non-fatal MIs.
In a prospective analysis of 60 newly diagnosed lower extremity PAD patients, Beckman and colleagues found that the risk of future cardiovascular events was independently associated with both lower tertiles of ABI and higher tertiles of CRP. 16 Furthermore, the addition of CRP to ABI resulted in the best prediction model for future vascular events, even after adjusting for cardiovascular risk factors and use of beta blockers, statins, and aspirin ( Figure 2 ). The prediction model was weakened if IL-6 was substituted for CRP, suggesting that CRP may be more sensitive for atherothrombotic events. Notably, the majority of events in PAD patients in this study were coronary or lower extremity revascularizations, thereby weakening the strength of the conclusions.
Markers of endothelial dysfunction predict risk in PAD patients
According to the response to injury model of atherosclerosis, arteries are subject to insults including smoking, diabetes, dyslipidemia, and genetic factors. In many, the result is endothelial dysfunction which has been associated with an inflammatory host response. 44, [60] [61] [62] This process leads to vascular remodeling followed by plaque formation and ultimately a complicated atherosclerotic lesion. 63 Flow-mediated dilation, a relatively simple and inexpensive test for endothelial dysfunction, has had promising results in studies of secondary risk assessment in patients with PAD. 64 Brevetti and colleagues prospectively evaluated the additive value of FMD to ABI for cardiovascular risk prediction. 65 They found that the adjusted cardiovascular event rate was higher in patients with an FMD below the median. Additionally, belowmedian FMD and ABI combined was more accurate in predicting risk than either alone, demonstrating a 13fold risk of cardiovascular events when both FMD and ABI were below the median. This study suggests that it is useful to add FMD testing to ABI measurement to risk stratify patients with lower extremity PAD. Pellegrino and colleagues evaluated a pathophysiologic basis for worse outcomes in patients with endothelial dysfunction when they stratified PAD patients by their baseline FMD and evaluated myocardial flow reserve in each patient. They found that although the patients did not have known cardiac disease, low FMD predicted poor coronary flow reserve. 66
Other novel approaches of secondary risk prediction in PAD
The future of cardiovascular risk prediction in PAD will likely include assessment of numerous molecular and genetic factors that contribute to cardiovascular disease. Associations between cellular adhesion molecules and markers of hemostasis such as fibrinogen and outcomes in patients with established PAD have been reported. 46, 47 Perhaps the most accurate assessments of thrombophilia, plaque stability, angiogenesis, and response to therapies will be possible with individualized genetic analysis. Promising studies of linkage analysis, whole genome association studies, and specific genetic epidemiologic studies have provided a basis for understanding risk in CHD. 67 The burgeoning science of cardiovascular genomics will certainly have a major impact in our understanding of risk prediction in PAD.
A new paradigm for predicting risk
Cardiovascular risk prediction in PAD patients to date has in general been defined by three major factors, including ABI (to some degree), clinical stage of the leg arterial disease and number of additional major vascular beds involved (coronary/cerebral). However, Figure 2 Three-dimensional representation of cardiovascular events in relation to levels of CRP and ABI. 16 Reprinted from ref. 16, copyright (2005) , with permission from Elsevier. emerging data suggest that systemic inflammation may independently affect the susceptibility of the patient with PAD to future acute events ( Figure 3 ).
Inflammation may affect regional cardiovascular outcomes very early in the natural history of PAD by promoting disease progression. In the Physician's Health Study, both the development of claudication and the need for surgical revascularization among those who developed lower extremity PAD was independently associated with baseline CRP measurements. 68 McDermott and colleagues have further described the effects of inflammation on functional limitations. They evaluated the function of 370 patients with lower extremity PAD versus controls. 69 Independent of ABI, CRP was inversely associated with 6-minute walk distance and summary performance scores. CRP was strongly predictive of the future risk of diminished physical functional ability in both symptomatic and asymptomatic patients with PAD. In a follow-up longitudinal study of annual functional performance in these patients, higher levels of CRP were associated with greater annual declines in the 6-minute walk performance. 70 McDermott's group also recently reported that PAD patients taking statins had less annual decline in multiple measures of performance, including the 6-minute walk performance. 71 After adjustment for other factors, the CRP level remained predictive of functional limitations, suggesting a potential causal association between inflammation and diminished functional capacity that could be modified by statins.
Conclusion
The goal of office-based cardiovascular risk assessment is early identification of all patients at risk who potentially could experience an adverse cardiovascular event in order to prevent future morbidity and mortality. However, in patients with established PAD, reliance on traditional cardiovascular risk equations and the ABI are not sufficient to define those patients at highest risk for future events. Not only are traditional cardiovascular risk equations derived from large epidemiologic studies on comparably healthy patients, but many of the variables are dichotomous and only assess major disease states. Given the highly increased risk of cardiovascular events in the PAD population, a more complete ability to risk stratify is of great importance. Available data suggest that the severity of hemodynamic disease based on the ABI level, the clinical stage of disease, the level of systemic inflammation, and the number of systemic vascular beds involved provide more complete information identifying who is at greatest risk. However, all of these factors have not been evaluated simultaneously in the same population. Thus, we do not know at this time which of these factors would remain independent predictors of risk if all were evaluated in the same multivariate model. Large epidemiologic studies specifically addressing each factor listed above, as independent predictors of risk in a PAD population, need to be performed in order to further clarify the best prediction tool. The goal of a secondary risk prediction tool in PAD would be to increase awareness of the practitioner who is responsible for implementing aggressive secondary preventive measures. Additionally, an objective prediction tool may increase patient awareness of risk and promote medical adherence and further efforts at smoking cessation.
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Figure 3
Risk of future cardiovascular morbidity and mortality in patients with lower extremity PAD (ϩ mild risk, ϩϩ moderate risk, ϩϩϩϩ highest risk). The assumption that ABI and clinical stage give similar information has not been validated.
